Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs.

Viral Immunol. 1999;12(2):117-29. Unique Identifier : AIDSLINE MED/99339703
Meyer D; Torres JV; Department of Medical Microbiology and Immunology, School of; Medicine, University of California, Davis 95616, USA.

Abstract: We previously reported the broad humoral immunogenicity of peptides synthesized according to the cumulative variability of an epitope (1,16). These peptides, hypervariable epitope constructs (HECs), are designed to represent the envelope glycoproteins of several isolates of the simian immunodeficiency virus (SIV). When HEC peptides were conjugated to palmitic acid and palmitic acid ester (lipoHECs), they promoted the induction of cellular immune responses. SIV envelope lipoHEC immunization of BALB/c and ICR mice resulted in up to 80% cytotoxic T lymphocyte (CTL) lysis of SIV envelope-expressing target cells and SIV envelope-specific delayed type hypersensitivity (DTH). This DTH response was significantly higher than that of single peptide controls, and the response peaked at 24 hours. Strong SIV envelope-specific T-cell proliferative responses were also induced in mice with stimulation indexes higher than 20 for spleen cells and higher than 10 for lymph node cells. Overall, our results demonstrate that conjugation of these variable synthetic peptides to a lipid moiety results in an immunogen capable of inducing strong and cross-reactive cellular immune responses.

Keywords: JOURNAL ARTICLE Amino Acid Sequence Animal Cell Division Epitopes, T-Lymphocyte/*IMMUNOLOGY Female Human Hypersensitivity, Delayed/IMMUNOLOGY Mice Mice, Inbred BALB C Mice, Inbred ICR Molecular Sequence Data Peptides/CHEMICAL SYNTHESIS/IMMUNOLOGY Support, U.S. Gov't, P.H.S. SIV/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/*IMMUNOLOGY T-Lymphocytes, Helper-Inducer/*IMMUNOLOGY Viral Envelope Proteins/GENETICS/*IMMUNOLOGY
991130
A99B1143

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .